Item 8.01 Other Events.

On February 18, 2021, Bristol-Myers Squibb Company ("Bristol Myers Squibb") issued a press release announcing the early tender results for its previously announced cash tender offers (the "Offers") to purchase notes issued by Bristol Myers Squibb and Celgene Corporation, Bristol Myers Squibb's wholly owned subsidiary (the "Offerors"), for an aggregate purchase price of up to $4.0 billion.

On February 19, 2021, the Offerors also issued a press release announcing the pricing terms of such previously announced Offers.

The Offers are subject to the terms and conditions described in the Offer to Purchase dated February 4, 2021 (as it may be amended or supplemented from time to time), which sets forth a detailed description of the Offers.

Copies of the press releases are attached hereto as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and incorporated herein in their entirety.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are included as part of this Current Report on Form 8-K:



Exhibit
  No.     Description

 99.1     Press release of Bristol-Myers Squibb Company dated February 18, 2021.
 99.2     Press release of Bristol-Myers Squibb Company dated February 19, 2021.
          The cover page from this Current Report on Form 8-K formatted in Inline
  104     XBRL (included as Exhibit 101).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses